Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA

Executive Summary

FDA’s proposal to limit collection of certain safety data in late-stage and post-marketing clinical trials will only reduce the burden on sponsors, investigators and patients if drug regulators across the globe agree to the concept, pharmaceutical manufacturers say.

Advertisement

Related Content

FDA’s Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
Large Simple Trials Need FDA Boost, IoM Report Says
FDA’s Guide For Selectively Collecting Safety Data
ASCO Seeks More Aggressive Approach On Limiting Safety Data Collection
ASCO Seeks More Aggressive Approach On Limiting Safety Data Collection

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel